hy said on the 12th that it signed a strategic business partnership with the new drug development specialist corporations ImmunoBiome.
ImmunoBiome has the functional ingredient development platform "Avatiome" and the microbiome diagnosis and personalized recommendation platform "IM.BERT." Avatiome is a preclinical model that reproduces a human-like environment and can comprehensively evaluate immune and gut microbiota responses, shortening research time and increasing the likelihood of clinical success.
IM.BERT is a platform that predicts health status through AI-based gut data analysis and proposes solutions suitable for each individual's gut environment. Based on pre-trained microbiome data, it has built a disease state prediction model, and depending on the analysis results, it can recommend probiotics and health functional foods, hy said.
Starting with gut environment analysis using a fecal test kit, the two companies will push to develop personalized probiotics and health functional foods. They plan to expand collaboration into preventive and management-centered gut health solutions and the medical food space through diagnostic models linked with hospital checkup data.
An hy official said, "We will create new opportunities by combining hy's accumulated probiotics technology with an AI-based data analysis platform," adding, "This agreement will be an important stepping stone for leaping forward as a microbiome corporations."